Onco-Innovations' PKNP Technology Shows Promising Low Toxicity in Study

Onco-Innovations Limited has announced promising results for its nanoparticle formulation of Polynucleotide Kinase 3'-Phosphatase (PNKP) technology. Research from the University of Alberta demonstrated its impressive low toxicity levels. The study showed that the technology was well-tolerated in mice with colorectal cancer, suggesting fewer potential side effects in future treatments.

The research involved in-vivo studies with mice, where the PKNP formulation was used over 22 days without observed adverse effects. A dose escalation study confirmed the safety of the PNKP inhibitors at specific doses. These findings are crucial for developing safer oncology treatments.

CEO Thomas O'Shaughnessy highlighted the technology's potential for safer cancer therapies, emphasizing its low toxicity. Continued research and regulatory compliance will steer further development and potential commercialization.